Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe conducted a matched case-control study among all individuals eligible for sotrovi...

Full description

Saved in:
Bibliographic Details
Main Author: Ahmed, Zaqout (author)
Other Authors: Almaslamani, Muna A. (author), Chemaitelly, Hiam (author), Hashim, Samar A. (author), Ittaman, Ajithkumar (author), Alimam, Abeir (author), Rustom, Fatma (author), Daghfal, Joanne (author), Abukhattab, Mohammed (author), AlMukdad, Sawsan (author), Kaleeckal, Anvar Hassan (author), Latif, Ali Nizar (author), Butt, Adeel A. (author), Bertollini, Roberto (author), Al-Khal, Abdullatif (author), Omrani, Ali S. (author), Abu-Raddad, Laith J. (author)
Format: article
Published: 2022
Subjects:
COVID-19
SARS-CoV-2
Sotrovimab
Omicron
BA.2
Epidemiology
Online Access:http://dx.doi.org/10.1016/j.ijid.2022.09.023
https://www.sciencedirect.com/science/article/pii/S1201971222005227
http://hdl.handle.net/10576/45351
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items